Article ID Journal Published Year Pages File Type
3268208 Endocrinology and Metabolism Clinics of North America 2009 13 Pages PDF
Abstract

The treatment of elevated levels of low-density lipoprotein cholesterol is standard medical practice supported by conclusive outcome data. Less definitive information exists for hypertriglyceridemia. Only in the setting of severe hyperchylomicronemia is the benefit of triglyceride lowering clear: it is a means to reduce the risk of pancreatitis. The relationship of triglycerides and cardiovascular disease is still unclear. Moreover, the cardiovascular benefits of reducing triglycerides and of using triglyceride-lowering medications remain unproved. Nonetheless it has become almost standard to reduce the levels of triglyceride-rich lipoproteins that are a major component of plasma non–high-density lipoprotein cholesterol.

Related Topics
Health Sciences Medicine and Dentistry Endocrinology, Diabetes and Metabolism
Authors
,